论文部分内容阅读
自2008年至今,有大量关于慢性HBV感染的自然史和治疗的最新数据不断涌现。其中包括慢性HBV感染的无症状感染者,以社区为基础的队列研究,HBV基因型的作用,非药物诱导的自然HBV变异型毒株,无创性肝纤维化评估方法的应用,HBsAg定量在临床中的应用,更有效的新治疗药物和新治疗方案等等。来自亚太地区的专家审查和评估了相关数据,并共同商讨了近年来报道的最有意义的发现,基于此,对2008年版的亚太地区慢性乙型肝炎治疗共识进行修订,同时对2008年版治疗指南定义的关键词组进行了修订。修订后的指南包括以下几方面内容:一般治疗,肝纤维化评价适应证,何时开始治疗或停药,初始抗病毒治疗药物的选择,如何监测治疗中和治疗后的患者。关于特殊人群的治疗建议中包括了对妊娠妇女,已发生耐药,合并其他病毒感染,肝功能失代偿,接受免疫抑制治疗、化疗,肝移植或肝细胞癌患者的具体治疗建议。
Since 2008, there is a growing body of recent data on the natural history and treatment of chronic HBV infection. Among them are asymptomatic patients with chronic HBV infection, community-based cohort studies, the role of HBV genotypes, the use of non-drug-induced natural variant HBV strains, and non-invasive assessment of liver fibrosis. HBsAg quantification is clinically In the application of more effective new therapies and new treatment programs and so on. Experts from the Asia-Pacific region reviewed and evaluated relevant data and jointly discussed the most significant findings reported in recent years. Based on this, we revised the 2008 version of the consensus on treatment of chronic hepatitis B in the Asia Pacific region and revised the 2008 version of the treatment guidelines The definition of key phrases was revised. The revised guidelines include the following: general treatment, indications for evaluating liver fibrosis, when to start treatment or discontinuation, selection of initial ARVs and how to monitor patients during and after treatment. Treatment recommendations for specific populations include specific treatment recommendations for pregnant women, those who have developed resistance, other viral infections, decompensated liver disease, immunosuppressive therapy, chemotherapy, liver transplantation, or hepatocellular carcinoma.